Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical innovator specializing in drug discovery technologies and strategic licensing partnerships. This page aggregates official updates about the company's research advancements, financial milestones, and Captisol® technology applications.
Investors and industry professionals will find timely updates on earnings reports, regulatory developments, and partnership announcements. Our curated collection includes press releases about new licensing agreements, clinical trial progress, and intellectual property expansions that shape LGND's position in the pharmaceutical sector.
Key areas of coverage include updates on royalty-bearing partnerships, Captisol® formulation breakthroughs, and corporate financial strategies. Bookmark this page to monitor how Ligand's lean operational model and diversified revenue streams continue to drive innovation in drug development.
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) partners with the University of Minnesota and CURx Pharmaceuticals to present new data on Captisol-enabled™ Topiramate Injection as a potential substitute for oral topiramate in treating neurological conditions like epilepsy. The IV formulation of topiramate simplifies replacement therapy, allowing for proper dosing in various clinical scenarios. Ligand holds the license for IV topiramate and is entitled to milestone payments and royalties on global sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
-
Rhea-AI Summary
Ligand Pharmaceuticals announces the launch of Pelthos Therapeutics and the appointment of Scott Plesha as CEO. Pelthos aims to commercialize ZELSUVMI, a topical gel for molluscum contagiosum, expected to be available in late 2024. The product received FDA approval and is developed using Pelthos' proprietary technology platform. Ligand acquired the rights to ZELSUVMI from Novan, Inc. in 2023. Scott Plesha brings over 30 years of pharmaceutical industry experience to the role, with a successful track record in building commercial organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
-
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) CEO and CFO to participate in a fireside chat at the Barclays Healthcare Conference. The event is on March 14, 2024, in Miami.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) granted a non-qualified stock option award to an employee for 15,100 shares of common stock under the Inducement Plan. The options have an exercise price of $78.70 per share, a ten-year term, and will vest over four years. This award aims to attract and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
-
Rhea-AI Summary
Ligand Pharmaceuticals' partner Eisai receives approval for Fycompa injection formulation in Japan, utilizing Ligand's Captisol technology. Fycompa is a novel antiepileptic drug, enhancing treatment options for patients with epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
-
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated appoints Richard Baxter as Senior Vice President of Investment Operations and Karen Reeves, M.D., as Senior Vice President of Clinical Strategy and Investments. The company aims to enhance deal capabilities and capitalize on industry developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) will announce full year and fourth quarter 2023 financial results on February 27, 2024. A conference call will be held to discuss financial results and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
-
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) granted non-qualified stock option awards to two non-executive employees, totaling 93,700 shares, 32,750 restricted stock units, and 40,000 performance stock units. The options have an exercise price of $74.17 per share and will vest over four years. RSUs will vest over three years, and PSUs will vest based on company performance objectives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
-
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) announced FDA approval of ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum in adults and pediatric patients. ZELSUVMI is the first novel drug for this treatment and the first and only topical prescription medication that can be applied by patients, parents, or caregivers at home. It is expected to be commercially available in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City to provide an overview of the company’s business model, investment selection process, 2024 guidance, and portfolio progress. Ligand focuses on investing in late-clinical stage assets and licensing the Captisol® technology platform to generate revenues for shareholders. The company has undergone a restructuring to focus on a lean infrastructure and high-margin business. Management highlighted late-stage assets and potential pipeline events in 2024, along with recent transactions, the Captisol Technology Platform, and the 2024 investment outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
Ligand Pharma
Nasdaq:LGND
LGND Rankings
LGND Stock Data
2.09B
18.84M
2.06%
98.51%
4.05%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO